When Can I Buy Akanda Stock?

In stark contrast to the madness of 2021, the 2022 IPO market has effectively all but dried up. Fears around inflation and the general volatile nature of today’s market have caused companies planning to debut to postpone or hold off. Firms such as Justworks and WeTransfer both made eleventh-hour decisions to cancel impending market debuts.

One company attempting to buck the trend, however, is Akanda.

What does Akanda do?

Akanda is a UK-based medicinal cannabis company and wellness platform. The firm is building what it calls “a seed-to-patient supply chain,” which will connect patients based primarily in the UK and Europe with cannabis-related products grown at its cultivation campus in the Kingdom of Lesotho in Africa.

When can I buy Akanda stock?

Akanda will start trading today on the NASDAQ stock exchange. It will trade under the ticker symbol “AKAN” and will be initially priced at $4 per share. Four million common shares will be made available, which would see Akanda raise $16 million from going public.

Akanda’s financials

As of now, the company has no revenue to speak of. This is due to the firm being in a “start-up phase” while it develops its African-based cultivation site. Also, the site has yet to complete a full cannabis harvest cycle under accredited conditions. This first cycle is expected to conclude in March or April of this year.

Akanda has incurred a net loss of $2.3 million and $1.4 million respectively in 2020 and 2019, with much of this attributed to consulting and professional fee expenses. In the nine months ending September 30, 2021, the company had incurred a net loss of over $3.6 million. This stark increase is due to increase operating expenses associated with the build-out of its cultivation site.

Akanda’s growth potential

While the medicinal cannabis market was reportedly worth $16.47 billion in 2021, it is expected to swell to $46.18 billion by 2026, with a forecasted CAGR of 22.9%. The company would have to scale tremendously quickly in order to try and capitalize on this boom in the industry. 

Akanda, in its own F-1 filing, admits that “the company is in the preliminary stages of its planned operations and has not yet determined whether its processes and business plans are economically viable.” Strict regulation across Europe — Akanda’s primary market — will also serve to constrain growth at this early stage.

Competition is also rife in the industry, with some of the larger American companies looking at the European market to try and build out their offerings. Notably, Curaleaf purchased European-based Emmc Life Sciences last year to bolster its global footing and allow it to expand to eight new territories. 

While Akanda has every chance to grow and develop, it just seems too early in its journey to recommend investing. Too many questions need to be answered, not least, when and how does it plan to make any money?

Market AnalysisAkanda
Pádraig BolgerPádraig Bolger
  • Pádraig Bolger
  • Financial Writer at MyWallSt

  • Pádraig’s favorite stock is Nike. Growing up as a sports fanatic, seeing Nike collaborate with athletes like Jordan, Lebron, and Ronaldo inspired him and cemented the brand in his mind. Now, despite having failed miserably in his attempts to earn a fabled Nike sponsorship, he still believes in the innovation and creativity behind Nike and is convinced they will only grow stronger as the world’s leading sports brand.

Read More

Why has Twitter underperformed the market?Why has Twitter underperformed the market?

What Is Going On Between Elon Musk and Twitter?

Now that Twitter looks to accept a buyout offer from Elon Musk, despite using a “poison pill,” what could happen next?

Expert Opinion
Rory CarronRory Carron
  • Rory Carron
  • Apr 25, 2022

Why is Tesla Choosing Right Now to Split Its Stock?Why is Tesla Choosing Right Now to Split Its Stock?

When is Tesla Going To Split Its Stock?

The announcement of a planned stock split sent Tesla shares soaring yesterday, but why is the company looking to do this right now?

Market Analysis
Pádraig BolgerPádraig Bolger
  • Pádraig Bolger
  • Apr 25, 2022

Are Pfizer and NextEra Energy recession-proof stocks?Are Pfizer and NextEra Energy recession-proof stocks?

Are Pfizer and NextEra Energy Recession-Proof Stocks?

An inverted yield curve has left economists and analysts concerned that the US is tumbling towards a recession. As a result, investors are now looking for places they can put their money in order to minimise any potential losses.

Market Analysis
  • Opto
  • Apr 25, 2022

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button